Researchers affiliated with The International Acute Myeloid Leukemia Study have reported that the use of Neupogen (filgrastim) to support intensive induction and consolidation chemotherapy does not affect long-term survival of patients with acute myeloid leukemia (AML). The details of this randomized Phase III study appeared in the journal Leukemia .
The study included a total of 521 adult patients with AML who were randomly allocated to receive Neupogen or placebo following induction and consolidation chemotherapy. Neupogen hastened neutrophil recovery by 5 days compared to placebo. This was accompanied by less fever, fewer parenteral antibiotics, including amphotericin B, and shorter hospitalization times with no apparent impact on survival or relapses.